The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.
 
James L. Gulley
Consulting or Advisory Role - Prime Oncology; TRM Oncology
Travel, Accommodations, Expenses - Prime Oncology; TRM Oncology
 
Jeannie Lorraine Giacchino
Employment - Bavarian Nordic
Leadership - Bavarian Nordic
Stock and Other Ownership Interests - Bavarian Nordic
Travel, Accommodations, Expenses - Bavarian Nordic
 
James Bradley Breitmeyer
Employment - Bavarian Nordic
Leadership - Bavarian Nordic; Zogenix
Stock and Other Ownership Interests - Bavarian Nordic; Zogenix
Research Funding - Bavarian Nordic (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent(s)
Travel, Accommodations, Expenses - Bavarian Nordic; Zogenix
 
Alexis J. Franzusoff
Employment - Bavarian Nordic
Stock and Other Ownership Interests - AstraZeneca
Research Funding - Bavarian Nordic
Patents, Royalties, Other Intellectual Property - AstraZeneca; Bavarian Nordic
Travel, Accommodations, Expenses - Bavarian Nordic
 
Dennis Panicali
Employment - Bavarian Nordic
Leadership - Bavarian Nordic
Stock and Other Ownership Interests - Bavarian Nordic
Patents, Royalties, Other Intellectual Property - Royalties
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst); EMD Serono (Inst); GlobeImmune (Inst)
Patents, Royalties, Other Intellectual Property - unknown (Inst)
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi